Suvorexant: what did the insomnia trial show?
Two trials randomized 1,021 and 1,019 adults. Nightly suvorexant doses were 20 or 40 mg for ages 18–64 and 15 or 30 mg for ages 65 and older, versus placebo for three months.
The 20/15 mg groups improved reported total sleep time and laboratory overnight wakefulness at all assessed time points. Sleep-onset measures improved at most, but not all, time points. Fewer than 5% discontinued because of adverse events.
The trials primarily focused on the higher 40/30 mg groups, with fewer participants assigned to 20/15 mg. These historical study doses are not a prescribing recommendation or a direct comparison with Dayvigo.
These results apply to the studied population, formulation and follow-up.
What might this mean, and what would change the interpretation?
This is a selected trial summary, not a full literature review or formal quality appraisal.
What would clarify this: Further studies of long-term outcomes and different patient groups.
Findings reviewed · abstract
Checked Sep 23, 2026 against the linked abstract. This reading note is not a formal risk-of-bias appraisal.